MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on March 15, 2005; DOI: 10.1124/mol.105.011056

0026-895X/05/6706-2032-2039$20.00
Mol Pharmacol 67:2032-2039, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.011056v1
67/6/2032    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, G.
Right arrow Articles by Loh, H. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, G.
Right arrow Articles by Loh, H. H.

DNA Methylation-Related Chromatin Modification in the Regulation of Mouse {delta}-Opioid Receptor Gene

Guilin Wang, Tiancheng Liu, Li-Na Wei, Ping-Yee Law, and Horace H. Loh

Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota

DNA methylation plays critical roles in gene-silencing through chromatin modification. We reported previously that promoter-region CpG methylation repressed mouse {delta}-opioid receptor (mDOR) gene expression. In the current study, we demonstrated that the methylation of mDOR gene promoter is correlated with a repressive chromatin structure that has less HaeIII and MspI nuclear accessibility and more deacetylated histone H3 and H4 than that of unmethylated mDOR promoter. Chromatin immunoprecipitation analysis showed the association of a methyl-CpG-binding domain protein 2 (MBD2) with methylated mDOR promoter. Transient expression of MBD2 enhanced the repression of partially methylated mDOR promoter activity, and this repression was partially reversed by treatment of trichostatin A, a specific histone deacetylase inhibitor, indicating that MBD2 may mediate DNA methylation-related chromatin modification through recruiting histone deacetylases to mDOR promoter region. In addition, trichostatin A treatment increased both methylated mDOR promoter activity in a transient transfection assay and endogenous mDOR mRNA level in Neuro2A cells. Taken together, these results demonstrate that the mDOR gene expression is regulated by DNA methylation-related chromatin modification, especially histone acetylation and deacetylation.

Received January 10, 2005; accepted March 14, 2005

Address correspondence to: Dr. Guilin Wang, 6-120 Jackson Hall, 321 Church St SE, Minneapolis, MN 55455. E-mail: wangx212{at}umn.edu




This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
C. K. Hwang, K. Y. Song, C. S. Kim, H. S. Choi, X.-H. Guo, P.-Y. Law, L.-N. Wei, and H. H. Loh
Evidence of Endogenous Mu Opioid Receptor Regulation by Epigenetic Control of the Promoters
Mol. Cell. Biol., July 1, 2007; 27(13): 4720 - 4736.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. T. Okino, D. Pookot, L.-C. Li, H. Zhao, S. Urakami, H. Shiina, M. Igawa, and R. Dahiya
Epigenetic Inactivation of the Dioxin-Responsive Cytochrome P4501A1 Gene in Human Prostate Cancer.
Cancer Res., August 1, 2006; 66(15): 7420 - 7428.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics